United-Guardian Reports First Quarter Results
Rhea-AI Summary
United-Guardian (NASDAQ:UG) reported Q1 2026 net sales of $2.87M versus $2.48M a year earlier and net income of $818,902 ($0.18/share) versus $560,895 ($0.12/share) in Q1 2025. Results included $303,133 settlement income and sales gains in pharmaceuticals and cosmetic ingredients.
Positive
- Net sales +15.8% year-over-year to $2,872,222
- Net income +46.0% year-over-year to $818,902
- $303,133 settlement income recognized in Q1 2026
- Pharmaceutical sales +24% in Q1 2026
- Cosmetic ingredient sales +21% in Q1 2026; ASI purchases +45%
Negative
- Cost of sales increased by 28.9% to $1,447,789
- Total costs and expenses rose by 19.2% to $2,229,773
- Provision for income taxes increased by 45.7% to $214,236
Key Figures
Market Reality Check
Peers on Argus
Pre-news, UG was up 4.32% while close peers showed mixed moves (e.g., RAY +2.19%, PHH -1.69%), and no peers appeared in the momentum scanner, pointing to company-specific factors over a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Annual results | Negative | +3.8% | FY2025 sales and earnings declined versus 2024 amid cosmetic weakness. |
| Nov 06 | Quarterly earnings | Negative | -6.3% | Q3 2025 sales and net income fell sharply on reduced ASI orders. |
| Aug 08 | Quarterly earnings | Negative | -0.5% | Q2 2025 revenue and earnings declined year-over-year despite some sequential gains. |
| May 08 | Quarterly earnings | Negative | +0.6% | Q1 2025 net sales and income dropped, led by cosmetic ingredient weakness. |
| Mar 21 | Annual results | Positive | -3.0% | FY2024 delivered double-digit sales and earnings growth across key segments. |
Earnings-related headlines have often produced contrarian reactions, with stock moves diverging from the apparent tone of results in 3 of the last 5 earnings events.
Over the last five earnings updates, United-Guardian has moved from strong FY 2024 growth to a weaker FY 2025, driven largely by cosmetic ingredient softness and distributor inventory issues. Quarterly 2025 releases highlighted declining sales and earnings, partly offset by resilient pharmaceuticals and medical lubricants. The current Q1 2026 report contrasts with that trend, showing higher sales and net income versus Q1 2025 and noting ASI’s return to regular purchasing and settlement income tied to prior Renacidin supply disruption.
Historical Comparison
Over the last five earnings releases, UG’s average next-day move was -1.07%, with frequent divergences between results tone and price reaction, underscoring historically uneven responses to earnings news.
Earnings events show a path from strong FY 2024 growth to a weaker FY 2025 as cosmetic ingredients softened, then to Q1 2026 where higher sales, net income, and resumption of normal ASI orders suggest early signs of operational recovery from prior inventory and supply disruptions.
Market Pulse Summary
This announcement highlights a rebound in Q1 2026, with higher net sales and net income versus Q1 2025, supported by 24% pharmaceutical and 21% cosmetic ingredient growth and settlement income tied to past Renacidin disruption. In context of earlier filings showing 2025 softness from cosmetic weakness and distributor inventory issues, this quarter suggests early normalization. Investors may watch future quarters for sustained demand from ASI, stability of Renacidin supply, and segment mix trends.
Key Terms
marketable securities financial
forward-looking statements regulatory
AI-generated analysis. Not financial advice.
HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from
Donna Vigilante, President of United-Guardian, stated, “I am happy to report that sales and earnings increased in the first quarter of 2026 compared with the first quarter of 2025. Our financial performance was primarily driven by increased sales of both our pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose by
“In addition to the increase in sales, our income for the quarter was also supplemented by settlement income we recognized from the contract manufacturer (“CM”) of Renacidin in connection with an unexpected shutdown at the CM’s facility in late 2023, which resulted in lost Renacidin sales.”
“With ASI resuming its regular purchasing pattern, new distribution agreements in place, increased emphasis on expanding our “natural” product lines, and our ongoing project to increase outreach and market penetration for Renacidin, we are optimistic that our sales will continue to increase in 2026.”
United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.
| Contact: | Donna Vigilante (631) 273-0900 dvigilante@u-g.com |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 UNITED-GUARDIAN, INC. STATEMENTS OF INCOME (UNAUDITED) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Net sales | $ | 2,872,222 | $ | 2,481,127 | |||
| Costs and expenses: | |||||||
| Cost of sales | 1,447,789 | 1,123,076 | |||||
| Operating expenses | 666,963 | 632,735 | |||||
| Research and development | 115,021 | 114,394 | |||||
| Total costs and expenses | 2,229,773 | 1,870,205 | |||||
| Income from operations | 642,449 | 610,922 | |||||
| Other income: | |||||||
| Investment income | 69,814 | 84,687 | |||||
| Net gain on marketable securities | 17,742 | 12,350 | |||||
| Settlement income | 303,133 | --- | |||||
| Total other income | 390,689 | 97,037 | |||||
| Income before provision for income taxes | 1,033,138 | 707,959 | |||||
| Provision for income taxes | 214,236 | 147,064 | |||||
| Net income | $ | 818,902 | $ | 560,895 | |||
| Earnings per common share (basic and diluted) | $ | 0.18 | $ | 0.12 | |||
| Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | |||||
